In the published article, there was an error in the Acknowledgments section. An acknowledgment that would have been included at the time of submission was not included due to inability to obtain the written approval required which has become available now.
A correction has been made to Acknowledgments. The section previously stated:
“The authors thank the staff and patients of Clifton Park Hospital for samples. We are grateful to the University of York Technology Facility for support with flow cytometry, cell sorting, confocal microscopy bioinformatics and proteomic analysis. We also thank the York Centre of Excellence in Mass Spectrometry. We thank Emily Taylor for assistance in isolating primary T cells”.
The corrected Acknowledgments appears below:
“The authors thank the staff and patients of Clifton Park Hospital for samples and Emily Taylor for assistance isolating primary T cells. We thank the University of York Technology Facility for support with flow cytometry, cell sorting, confocal microscopy and proteomic analysis as well as the York Centre of Excellence in Mass Spectrometry. The authors thank Gillian Gough, MRes student at Newcastle University, for contributions to acquisition, analysis, and interpretation of skin explant data.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
mesenchymal stromal cells, MSC subtypes, heterogeneity, immunomodulation, CD317, BST2, tetherin
Citation
Kay AG, Fox JM, Hewitson JP, Stone AP, Robertson S, James S, Wang X, Kapasa E, Yang XB and Genever PG (2022) Corrigendum: CD317-Positive Immune Stromal Cells in Human “Mesenchymal Stem Cell” Populations. Front. Immunol. 13:1111042. doi: 10.3389/fimmu.2022.1111042
Received
29 November 2022
Accepted
30 November 2022
Published
13 December 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2022 Kay, Fox, Hewitson, Stone, Robertson, James, Wang, Kapasa, Yang and Genever.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Paul G. Genever, paul.genever@york.ac.uk; Alasdair G. Kay, alasdair.g.kay@york.ac.uk
This article was submitted to Inflammation, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.